Arkolith/Insider Trading/RXDX/Form 4

Marshall Keith W

Chief Financial OfficerPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Jan 19, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$595K
Net Open-Market Flow
-$595K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 17, 2023Option exercise(M)5K$3.70$19K15K
Jan 17, 2023Sell(S)5K$119.00$595K10K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 17, 2023Option exercise(M)5K—$0118K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-004138) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML